- Home
- ESPR vs CPAC Comparison
ESPR vs CPAC Comparison
Compare ESPR & CPAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- CPAC
- Stock Information
- Founded
- ESPR 2008
- CPAC 1949
- Country
- ESPR United States
- CPAC Peru
- Employees
- ESPR N/A
- CPAC N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- CPAC Building Materials
- Sector
- ESPR Health Care
- CPAC Industrials
- Exchange
- ESPR Nasdaq
- CPAC Nasdaq
- Market Cap
- ESPR 399.0M
- CPAC 495.3M
- IPO Year
- ESPR 2013
- CPAC 2012
- Fundamental
- Price
- ESPR $2.30
- CPAC $5.38
- Analyst Decision
- ESPR Buy
- CPAC Sell
- Analyst Count
- ESPR 5
- CPAC 1
- Target Price
- ESPR $7.30
- CPAC $6.00
- AVG Volume (30 Days)
- ESPR 8.8M
- CPAC 9.0K
- Earning Date
- ESPR 11-07-2024
- CPAC 02-12-2025
- Dividend Yield
- ESPR N/A
- CPAC 10.08%
- EPS Growth
- ESPR N/A
- CPAC 7.38
- EPS
- ESPR N/A
- CPAC 0.12
- Revenue
- ESPR $295,451,000.00
- CPAC $527,798,215.00
- Revenue This Year
- ESPR $186.90
- CPAC N/A
- Revenue Next Year
- ESPR $31.10
- CPAC N/A
- P/E Ratio
- ESPR N/A
- CPAC $9.72
- Revenue Growth
- ESPR 187.12
- CPAC N/A
- 52 Week Low
- ESPR $1.58
- CPAC $4.95
- 52 Week High
- ESPR $3.94
- CPAC $6.65
- Technical
- Relative Strength Index (RSI)
- ESPR 44.79
- CPAC 30.99
- Support Level
- ESPR $2.12
- CPAC $5.31
- Resistance Level
- ESPR $2.54
- CPAC $6.10
- Average True Range (ATR)
- ESPR 0.35
- CPAC 0.21
- MACD
- ESPR -0.10
- CPAC -0.05
- Stochastic Oscillator
- ESPR 21.90
- CPAC 8.86
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About CPAC Cementos Pacasmayo S.A.A. (Each representing five)
Cementos Pacasmayo SAA is a Peruvian cement company that primarily produces, distributes, and sells cement and cement-related materials, such as concrete blocks and ready-mix concrete. The company's products are primarily used in construction. It also produces and sells quicklime for use in mining operations. The company sells its products mainly in the northern part of Peru. It owns three cement production facilities. Its flagship Pacasmayo facility is located in the northwest region of Peru, while its new cement plant in Piura and smaller Rioja facility are located in the northeast region of Peru.